Table of Contents
ISRN Obstetrics and Gynecology
Volume 2012, Article ID 245756, 11 pages
http://dx.doi.org/10.5402/2012/245756
Review Article

Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer

1Division of Gynecologic Oncology, “Angelo Nocivelli” Institute of Molecular Medicine, University of Brescia, 25123 Brescia, Italy
2Department of Clinical Pathology, Regional Center for Biomarkers, Azienda ULSS 12, 30122 Venice, Italy
3Department of Biomedical Sciences and Biotechnology, Medical Statistics Unit, University of Brescia, 25123 Brescia, Italy
4Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy
5Department of Obstetrics and Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06511, USA

Received 20 February 2012; Accepted 3 April 2012

Academic Editors: E. Ginsburg and Y. S. Song

Copyright © 2012 Elisabetta Bandiera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [21 citations]

The following is the list of published articles that have cited the current article.

  • Khanh Vinh Quốc Lu'o'ng, and Lan Thi Hoàng Nguyễn, “The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.,” Cancer management and research, vol. 4, pp. 431–45, 2012. View at Publisher · View at Google Scholar
  • Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini, and Simone Ferrero, “Monoclonal antibodies therapies for ovarian cancer,” Expert Opinion on Biological Therapy, vol. 13, no. 5, pp. 739–764, 2013. View at Publisher · View at Google Scholar
  • Dominic Varga, Miriam Deniz, Lukas Schwentner, and Lisa Wiesmueller, “Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects,” International Journal Of Molecular Sciences, vol. 14, no. 1, pp. 640–673, 2013. View at Publisher · View at Google Scholar
  • L. N. R. Alves, E. V. Wolfgramm, A. K. de Castro Neto, and I. D. Louro, “Analysis of microsatellite instability and loss of heterozygosity in ovarian cancer: a study in the population of Espirito Santo, Brazil,” Genetics and Molecular Research, vol. 12, no. 2, pp. 1996–2001, 2013. View at Publisher · View at Google Scholar
  • Kazuhiro Tamura, Mikihiro Yoshie, Eri Miyajima, Mika Kano, and Eiichi Tachikawa, “Stathmin Regulates Hypoxia-Inducible Factor-1 Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma,” ISRN Pharmacology, vol. 2013, pp. 1–8, 2013. View at Publisher · View at Google Scholar
  • Zhi-Qiang Ling, Wei Chen, Wei-Min Mao, Xiao-Ling Xu, and Ya-Ping Xu, “The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: A meta-analysis,” Cancer Biomarkers, vol. 13, no. 2, pp. 105–113, 2013. View at Publisher · View at Google Scholar
  • Gerasimos Aravantinos, and Dimitrios Pectasides, “Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review,” Journal of Ovarian Research, vol. 7, 2014. View at Publisher · View at Google Scholar
  • Amanda F. Baker, Scott W. Malm, Ritu Pandey, Cindy Laughren, Haiyan Cui, Denise Roe, and Setsuko K. Chambers, “Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer,” Cancer Microenvironment, 2015. View at Publisher · View at Google Scholar
  • A. Coosemans, J. Decoene, T. Baert, A. Laenen, A. Kasran, T. Verschuere, S. Seys, and I. Vergote, “Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course,” OncoImmunology, pp. 00–00, 2015. View at Publisher · View at Google Scholar
  • Bozena Dobrzycka, Beata Mackowiak-Matejczyk, Katarzyna Maria Terlikowska, Bozena Kulesza-Bronczyk, Maciej Kinalski, and Slawomir Jerzy Terlikowski, “Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  • Hiroyuki Yoshida, Akira Yabuno, and Keiichi Fujiwara, “Critical appraisal of bevacizumab in the treatment of ovarian cancer.,” Drug design, development and therapy, vol. 9, pp. 2351–8, 2015. View at Publisher · View at Google Scholar
  • Heather J Bax, Debra H Josephs, Giulia Pellizzari, James F Spicer, Ana Montes, and Sophia N Karagiannis, “Therapeutic targets and new directions for antibodies developed for ovarian cancer,” mAbs, pp. 00–00, 2016. View at Publisher · View at Google Scholar
  • Justin Sapiezynski, Oleh Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko, “Precision targeted therapy of ovarian cancer,” Journal of Controlled Release, 2016. View at Publisher · View at Google Scholar
  • Hongbo Wang, and Anna M. Mahecha, “The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer,” OncoTargets and Therapy, vol. 10, pp. 4617–4624, 2017. View at Publisher · View at Google Scholar
  • Raffaele Palmirotta, Erica Silvestris, Stella D?Oronzo, Angela Cardascia, and Franco Silvestris, “Ovarian cancer: novel molecular aspects for clinical assessment,” Critical Reviews in Oncology/Hematology, 2017. View at Publisher · View at Google Scholar
  • Dana M. Chase, David J. Chaplin, and Bradley J. Monk, “The development and use of vascular targeted therapy in ovarian cancer,” Gynecologic Oncology, 2017. View at Publisher · View at Google Scholar
  • Paul DiSilvestro, and Angeles Alvarez Secord, “Maintenance Treatment of Recurrent Ovarian Cancer: Is It Ready for Prime Time?,” Cancer Treatment Reviews, 2018. View at Publisher · View at Google Scholar
  • Luisa Bonilla, Amit Oza, and Stephanie Lheureux, “Emerging growth factor receptor antagonists for ovarian cancer treatment,” Expert Opinion on Emerging Drugs, pp. 1–16, 2018. View at Publisher · View at Google Scholar
  • Monica Hagan Vetter, and John L. Hays, “Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions,” Clinical Therapeutics, 2018. View at Publisher · View at Google Scholar
  • Amit Samani, Charleen Chan, and Jonathan Krell, “Novel Systemic Treatments in High Grade Ovarian Cancer,” Ovarian Cancer - From Pathogenesis to Treatment, 2018. View at Publisher · View at Google Scholar
  • Erica Silvestris, Stella D’Oronzo, Anna Passarelli, Eleonora Pellè, Rosalba De Nola, Raffaele Palmirotta, and Franco Silvestris, “Molecular Assessment of Ovarian Cancer and Translation to Clinical Management,” Oncogenomics, pp. 501–519, 2019. View at Publisher · View at Google Scholar